These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

390 related articles for article (PubMed ID: 32893999)

  • 21. Ocular Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors in Lung Cancer.
    Zhou L; Wei X
    Front Immunol; 2021; 12():701951. PubMed ID: 34504488
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Management of immune checkpoint inhibitor-related rheumatic adverse events.
    Zhou J; Wang H; Guo X; Wang Q; Duan L; Si X; Zhang L; Liu X; Li Y; Zhang W; Zhang L
    Thorac Cancer; 2020 Jan; 11(1):198-202. PubMed ID: 31762209
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical diagnosis and treatment recommendations for immune checkpoint inhibitor-related hematological adverse events.
    Zhuang J; Du J; Guo X; Zhou J; Duan L; Qiu W; Si X; Zhang L; Li Y; Liu X; Wang H; Zhou D; Zhang L
    Thorac Cancer; 2020 Mar; 11(3):799-804. PubMed ID: 32017466
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis.
    Larkin J; Chmielowski B; Lao CD; Hodi FS; Sharfman W; Weber J; Suijkerbuijk KPM; Azevedo S; Li H; Reshef D; Avila A; Reardon DA
    Oncologist; 2017 Jun; 22(6):709-718. PubMed ID: 28495807
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immune-related adverse events associated with immune checkpoint inhibitors in patients with cancer.
    Sengul Samanci N; Cikman DI; Oruc K; Bedir S; Çelik E; Degerli E; Derin S; Demirelli FH; Özgüroğlu M
    Tumori; 2021 Aug; 107(4):304-310. PubMed ID: 32935638
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Fatal Case of Immune Checkpoint Inhibitor-Mediated Myasthenia Gravis, Myositis, and Cardiomyopathy Overlap Syndrome in Urothelial Carcinoma.
    Newman MT; Bikhchandani M
    Cancer Rep (Hoboken); 2024 Jul; 7(7):e2140. PubMed ID: 39041627
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rheumatic immune-related adverse events induced by immune checkpoint inhibitors.
    Zhong H; Zhou J; Xu D; Zeng X
    Asia Pac J Clin Oncol; 2021 Jun; 17(3):178-185. PubMed ID: 32717098
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Proposed diagnostic and treatment paradigm for high-grade neurological complications of immune checkpoint inhibitors.
    Anderson D; Beecher G; Nathoo N; Smylie M; McCombe JA; Walker J; Jassal R
    Neurooncol Pract; 2019 Sep; 6(5):340-345. PubMed ID: 31555448
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bone fracture as a novel immune-related adverse event with immune checkpoint inhibitors: Case series and large-scale pharmacovigilance analysis.
    Filippini DM; Gatti M; Di Martino V; Cavalieri S; Fusaroli M; Ardizzoni A; Raschi E; Licitra L
    Int J Cancer; 2021 Aug; 149(3):675-683. PubMed ID: 33844854
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitor Therapy.
    Ho AK; Ho AM; Cooksley T; Nguyen G; Erb J; Mizubuti GB
    Anesth Analg; 2021 Feb; 132(2):374-383. PubMed ID: 33009134
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Peripheral Neuropathy and Muscle Disorders as Immune-Related Adverse Events].
    Suzuki S
    Brain Nerve; 2024 May; 76(5):605-611. PubMed ID: 38741503
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immune-related Adverse Events and Survival in Solid Tumors Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.
    Petrelli F; Grizzi G; Ghidini M; Ghidini A; Ratti M; Panni S; Cabiddu M; Ghilardi M; Borgonovo K; Parati MC; Tomasello G; Barni S; Berruti A; Brighenti M
    J Immunother; 2020 Jan; 43(1):1-7. PubMed ID: 31574022
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety of immune checkpoint inhibitor rechallenge after severe immune-related adverse events: a retrospective analysis.
    Eldani C; Kostine M; Faure M; Lazaro E; Rigothier C; Hiriart JB; Teulières B; Poullenot F; Haissaguerre M; Zysman M; Veillon R; Vergnenegre C; Issa N; Domblides C; Mary-Prey S; Beylot-Barry M; Pham-Ledard A; Dutriaux C; Sole G; Duval F; Gerard E
    Front Oncol; 2024; 14():1403658. PubMed ID: 39040444
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immune checkpoint inhibitors-induced neuromuscular toxicity: From pathogenesis to treatment.
    Psimaras D; Velasco R; Birzu C; Tamburin S; Lustberg M; Bruna J; Argyriou AA
    J Peripher Nerv Syst; 2019 Oct; 24 Suppl 2():S74-S85. PubMed ID: 31393660
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adverse events associated with immune checkpoint inhibitors in patients with breast cancer: A systematic review and meta-analysis.
    Balibegloo M; Nejadghaderi SA; Sadeghalvad M; Soleymanitabar A; Salehi Nezamabadi S; Saghazadeh A; Rezaei N
    Int Immunopharmacol; 2021 Jul; 96():107796. PubMed ID: 34162158
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Expert Perspective: Immune Checkpoint Inhibitors and Rheumatologic Complications.
    Cappelli LC; Bingham CO
    Arthritis Rheumatol; 2021 Apr; 73(4):553-565. PubMed ID: 33186490
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immune-Driven Pathogenesis of Neurotoxicity after Exposure of Cancer Patients to Immune Checkpoint Inhibitors.
    Vilariño N; Bruna J; Kalofonou F; Anastopoulou GG; Argyriou AA
    Int J Mol Sci; 2020 Aug; 21(16):. PubMed ID: 32796758
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical manifestation and management of immune checkpoint inhibitor-associated cardiotoxicity.
    Guo X; Wang H; Zhou J; Li Y; Duan L; Si X; Zhang L; Fang L; Zhang L
    Thorac Cancer; 2020 Feb; 11(2):475-480. PubMed ID: 31849171
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Management of immune-related adverse events associated with immune checkpoint inhibitors in cancer patients: a patient-centred approach.
    de La Rochefoucauld J; Noël N; Lambotte O
    Intern Emerg Med; 2020 Jun; 15(4):587-598. PubMed ID: 32144552
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Advances on immune-related adverse events associated with immune checkpoint inhibitors.
    Fan Y; Geng Y; Shen L; Zhang Z
    Front Med; 2021 Feb; 15(1):33-42. PubMed ID: 32779094
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.